Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians.

Tun NM, Oo TH.

Thrombosis. 2013;2013:183616. doi: 10.1155/2013/183616. Epub 2013 Feb 21.

2.

Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.

Feng W, Wu K, Liu Z, Kong G, Deng Z, Chen S, Wu Y, Chen M, Liu S, Wang H.

Thromb Res. 2015 Dec;136(6):1133-44. doi: 10.1016/j.thromres.2015.10.009. Epub 2015 Oct 20.

PMID:
26498222
3.
4.

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

Scaglione F.

Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. Review.

PMID:
23292752
5.

The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.

Mavrakanas T, Bounameaux H.

Pharmacol Ther. 2011 Apr;130(1):46-58. doi: 10.1016/j.pharmthera.2010.12.007. Epub 2010 Dec 24. Review.

PMID:
21185864
6.

Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs.

Ahrens I, Peter K, Lip GY, Bode C.

Discov Med. 2012 Jun;13(73):433-43. Review.

7.

The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature.

Tahir F, Riaz H, Riaz T, Badshah MB, Riaz IB, Hamza A, Mohiuddin H.

Thromb J. 2013 Sep 3;11(1):18. doi: 10.1186/1477-9560-11-18.

8.

Emerging anticoagulants.

Kennedy B, Gargoum FS, Kennedy L, Khan F, Curran DR, O'Connor TM.

Curr Med Chem. 2012;19(20):3388-416. Review.

PMID:
22680641
9.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
10.

The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants.

Hull RD, Gersh MH.

Curr Med Res Opin. 2015 Feb;31(2):197-210. doi: 10.1185/03007995.2014.975786. Epub 2014 Oct 30. Review.

PMID:
25299352
11.

Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.

Eriksson BI, Quinlan DJ, Eikelboom JW.

Annu Rev Med. 2011;62:41-57. doi: 10.1146/annurev-med-062209-095159. Review.

PMID:
21226611
12.

New oral anticoagulants for the treatment of venous thromboembolism.

Agnelli G, Becattini C, Franco L.

Best Pract Res Clin Haematol. 2013 Jun;26(2):151-61. doi: 10.1016/j.beha.2013.07.005. Epub 2013 Jul 22. Review.

PMID:
23953903
13.

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.

Robertson L, Kesteven P, McCaslin JE.

Cochrane Database Syst Rev. 2015 Dec 4;(12):CD010957. doi: 10.1002/14651858.CD010957.pub2. Review.

PMID:
26636644
14.

Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.

Marcy TR, Truong T, Rai A.

Consult Pharm. 2015 Nov;30(11):644-56. doi: 10.4140/TCP.n.2015.644. Review.

PMID:
26629800
15.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
16.

New anticoagulants: focus on venous thromboembolism.

Gómez-Outes A, Lecumberri R, Pozo C, Rocha E.

Curr Vasc Pharmacol. 2009 Jul;7(3):309-29. Review.

PMID:
19601856
17.

Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change.

Zikria JC, Ansell J.

Curr Opin Hematol. 2009 Sep;16(5):347-56. doi: 10.1097/MOH.0b013e32832ea2d7.

PMID:
19550318
18.

Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence.

Zalpour A, Oo TH.

Adv Hematol. 2015;2015:920361. doi: 10.1155/2015/920361. Epub 2015 Aug 16. Review.

19.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Baetz BE, Spinler SA.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354. Review.

PMID:
18956996
20.

The evolving role of dabigatran etexilate in clinical practice.

Hellenbart E, Drambarean B, Lee J, Nutescu EA.

Expert Opin Pharmacother. 2015;16(13):2053-72. Epub 2015 Aug 6.

PMID:
26245513

Supplemental Content

Support Center